All In Biotech

Drug Trial Radar · NCT05547061

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

91

Actual

Start

Apr 12, 2021

Primary completion

Jul 30, 2025

Study completion Feb 28, 2026

Sponsor

Lead sponsor
Cellbion Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This clinical trial is an open-label, single-arm, multi-center, escalation (Phase 1 Part B only), rater-blind (Phase 2 only), phase 1/2 trial to evaluate the diagnostic validity/safety of Ga-68-NGUL and efficacy/safety of Lu-177-DGUL on the anti-tumor activity that aims to simultaneously evaluate diagnostic and therapeutic validity.

Conditions

  • Prostate Cancer
  • mCRPC

Interventions

  • Lu-177-DGULDrug

    Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.

  • Ga-68-NGULDrug

    Administered intravenously during screening and every 12 weeks after the first administration of Lu-177-DGUL.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate(ORR) according to RECIST 1.1Time frame: From baseline until radiographic progression or death from any cause, whichever comes first. assessed up to 36 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Chonnam National University Hwasun Hospital

    Hwasun, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.